Retrospective Analysis of Onychomycosis Risk Factors Using the 2003-2014 National Inpatient Sample
Keywords:
onychomycosis, comorbidity, dermatophytosis, nail, nationalAbstract
Introduction: Onychomycosis, a fungal nail infection, is associated with significant morbidity and negative impact on quality of life. Therefore, understanding associated risk factors may inform onychomycosis screening guidelines.
Objectives: This retrospective study investigated common demographic and comorbidity risk factors among hospitalized patients using the National Inpatient Sample.
Methods: The 2003-2014 National Inpatient Sample (NIS) database was used to identify onychomycosis cases and age and sex matched controls in a 1:2 ratio. Chi-square tests and T-tests for independent samples were utilized to compare categorical and continuous patient factors. Demographic and comorbidity variables significant (p<0.05) on univariate analysis were analyzed via a multivariate regression model with Bonferroni correction (p<0.0029).
Results: 119,662 onychomycosis cases and 239,324 controls were identified. Compared to controls, onychomycosis patients frequently were White (69.0% vs. 68.0%; p<0.001), Black (17.9% vs. 5.8%; p<0.0001), and insured by Medicare or Medicaid (80.1% vs. 71.1%; p<0.0001). Patients had greater hospital stays (9.69 vs. 5.39 days; p<0.0001) and costs ($39,925 vs. $36,720; p<0.001) compared to controls. On multivariate analysis, onychomycosis was commonly associated with tinea pedis (OR: 111.993; p<0.0001), human immunodeficiency virus (OR: 4.372; p<0.001), venous insufficiency (OR: 6.916; p<0.0001), and psoriasis (OR: 3.668; p<0.001).
Conclusion: Onychomycosis patients had longer hospital stays and greater costs compared to controls. Black patients were disproportionately represented among cases compared to controls. Onychomycosis was associated with tinea pedis, venous insufficiency, human immunodeficiency virus, psoriasis, obesity (BMI ≥ 30 kg/m2), peripheral vascular disease, and diabetes with chronic complications, suggesting that inpatients with onychomycosis should be screened for these conditions.
References
Falotico JM, Lipner SR. Updated Perspectives on the Diagnosis and Management of Onychomycosis. Clin Cosmet Investig Dermatol. 2022;15:1933-1957. Published 2022 Sep 15. doi:10.2147/CCID.S362635
Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-1990. doi:10.1111/jdv.16394
Christenson JK, Peterson GM, Naunton M, et al. Challenges and Opportunities in the Management of Onychomycosis. J Fungi (Basel). 2018;4(3):87. Published 2018 Jul 24. doi:10.3390/jof4030087
Falotico JM, Lipner SR. Poor Antifungal Coverage for Onychomycosis in a Cross-Sectional Analysis of Medicaid Formularies. J Am Podiatr Med Assoc. 2022;112(5):21-221. doi:10.7547/21-221
Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38(5 Pt 1):702-704. doi:10.1016/s0190-9622(98)70199-9
Stewart CR, Algu L, Kamran R, et al. Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review. J Am Acad Dermatol. 2021;85(5):1227-1239. doi:10.1016/j.jaad.2020.05.143
Gupta AK, Mays RR. The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature. Skin Appendage Disord. 2018;4(4):208-216. doi:10.1159/000485632
Gregoriou S, Mpali N, Vrioni G, et al. Epidemiology of Onychomycosis in an Academic Nail Unit in South Greece during a Three-Year Period. Skin Appendage Disord. 2020;6(2):102-107. doi:10.1159/000504812
Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses. 2004;47(3-4):131-135. doi:10.1111/j.1439-0507.2004.00968.x
Rafat Z, Hashemi SJ, Saboor-Yaraghi AA, et al. A systematic review and meta-analysis on the epidemiology, casual agents and demographic characteristics of onychomycosis in Iran. J Mycol Med. 2019;29(3):265-272. doi:10.1016/j.mycmed.2019.05.004
Lipner SR, Hancock JE, Fleischer AB. The ambulatory care burden of nail conditions in the United States. J Dermatolog Treat. 2021;32(5):517-520. doi:10.1080/09546634.2019.1679337
Elewski BE, Tosti A. Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy. J Clin Aesthet Dermatol. 2015;8(11):38-42.
Bang CH, Yoon JW, Lee HJ, et al. Evaluation of relationships between onychomycosis and vascular diseases using sequential pattern mining. Sci Rep. 2018;8(1):17840. Published 2018 Dec 14. doi:10.1038/s41598-018-35909-z
Pichardo-Geisinger R, Mora DC, Newman JC, et al. Comorbidity of tinea pedis and onychomycosis and evaluation of risk factors in Latino immigrant poultry processing and other manual laborers. South Med J. 2014;107(6):374-379. doi:10.14423/01.SMJ.0000450705.67259.26
Dogra S, Kumar B, Bhansali A, et al. Epidemiology of onychomycosis in patients with diabetes mellitus in India. Int J Dermatol. 2002;41(10):647-651. doi:10.1046/j.1365-4362.2002.01528.x
Fukunaga A, Washio K, Ogura K, et al. Onychomycosis as a warning sign for peripheral arterial disease. Acta Derm Venereol. 2013;93(6):747-748. doi:10.2340/00015555-1576
Sigurgeirsson B, Steingrímsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol. 2004;18(1):48-51. doi:10.1111/j.1468-3083.2004.00851.x
Szepietowski JC, Reich A, Garlowska E, et al; Onychomycosis Epidemiology Study Group. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol. 2006;142(10):1279-1284. doi:10.1001/archderm.142.10.1279
Overview of the National (Nationwide) Inpatient Sample (NIS). Healthcare Cost & Utilization Project. Accessed May 15, 2023. https://hcup-us.ahrq.gov/nisoverview.jsp.
Moseley I, Ragi SD, Ouellette S, et al. Onychomycosis in underrepresented groups: an all of us database analysis. Arch Dermatol Res. 2023;315(3):647-651. doi:10.1007/s00403-022-02413-4
Chang MJ, Qiu Y, Lipner SR. Race reporting and representation in onychomycosis clinical trials: A systematic review. Mycoses. 2021;64(8):954-966. doi:10.1111/myc.13262
Benedict K, Gold JAW, Wu K, et al. High Frequency of Self-Diagnosis and Self-Treatment in a Nationally Representative Survey about Superficial Fungal Infections in Adults-United States, 2022. J Fungi (Basel). 2022;9(1):19. Published 2022 Dec 22. doi:10.3390/jof9010019
Kim DM, Suh MK, Ha GY. Onychomycosis in children: an experience of 59 cases. Ann Dermatol. 2013;25(3):327-334. doi:10.5021/ad.2013.25.3.327
Walling HW, Sniezek PJ. Distribution of toenail dystrophy predicts histologic diagnosis of onychomycosis. J Am Acad Dermatol. 2007;56(6):945-948. doi:10.1016/j.jaad.2006.06.003
Erbagci Z, Tuncel A, Zer Y, et al. A prospective epidemiologic survey on the prevalence of onychomycosis and dermatophytosis in male boarding school residents. Mycopathologia. 2005;159(3):347-352. doi:10.1007/s11046-004-5493-2
Markinson B, Caldwell B. Efinaconazole Topical Solution, 10% Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis. J Am Podiatr Med Assoc. 2015;105(5):407-411. doi:10.7547/14-088
Kulac M, Acar M, Karaca S, et al. Venous insufficiency in patients with toenail onychomycosis. J Ultrasound Med. 2005;24(8):1085-1089. doi:10.7863/jum.2005.24.8.1085
Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol. 2000;14(6):466-469. doi:10.1046/j.1468-3083.2000.00124.x
Cheng S, Chong L. A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong. Chin Med J (Engl). 2002;115(6):860-865.
Doner NYS, Ekmekci TR. Evaluation of obesity-associated dermatoses in obese and overweight individuals. Turkderm. 2011;45:146–51. doi:10.4274/turkderm.00908
Chang SJ, Hsu SC, Tien KJ, et al. Metabolic syndrome associated with toenail onychomycosis in Taiwanese with diabetes mellitus. Int J Dermatol. 2008;47(5):467-472. doi:10.1111/j.1365-4632.2008.03606.x
Cambuim II, Macêdo DP, Delgado M, et al. Avaliação clínica e micológica de onicomicose em pacientes brasileiros com HIV/AIDS [Clinical and mycological evaluation of onychomycosis among Brazilian HIV/AIDS patients]. Rev Soc Bras Med Trop. 2011;44(1):40-42. doi:10.1590/s0037-86822011000100010
Moreno-Coutiño G, Arenas R, Reyes-Terán G. Clinical presentation of onychomycosis in hiv/aids: a review of 280 mexican cases. Indian J Dermatol. 2011;56(1):120-121. doi:10.4103/0019-5154.77577
Flores-Bozo LR, Méndez-Flores S, Olvera-Rodríguez V, et al. Nail Changes in People Living with Human Immunodeficiency Virus: Observational and Cross-Sectional Study in a Third-Level Hospital. Skin Appendage Disord. 2022;8(5):368-375. doi:10.1159/000524257
Alves NCPOP, Moreira TA, Malvino LDS, et al. Onychomycosis in Psoriatic Patients with Nail Disorders: Aetiological Agents and Immunosuppressive Therapy. Dermatol Res Pract. 2020;2020:7209518. Published 2020 May 2. doi:10.1155/2020/7209518 (29)
Tsentemeidou A, Vyzantiadis TA, Kyriakou A, et al. Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: Results of a pilot study. Mycoses. 2017;60(12):830-835. doi:10.1111/myc.12681
Leibovici V, Hershko K, Ingber A, et al. Increased prevalence of onychomycosis among psoriatic patients in Israel. Acta Derm Venereol. 2008;88(1):31-33. doi:10.2340/00015555-0323
Kaçar N, Ergin S, Ergin C, et al. The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: a prospective controlled trial. Clin Exp Dermatol. 2007;32(1):1-5. doi:10.1111/j.1365-2230.2006.02215.x
Trovato L, Calvo M, De Pasquale R, et al. Prevalence of Onychomycosis in Diabetic Patients: A Case-Control Study Performed at University Hospital Policlinico in Catania. J Fungi (Basel). 2022;8(9):922. Published 2022 Aug 30. doi:10.3390/jof8090922
Takehara K, Oe M, Tsunemi Y, et al. Factors associated with presence and severity of toenail onychomycosis in patients with diabetes: a cross-sectional study. Int J Nurs Stud. 2011;48(9):1101-1108. doi:10.1016/j.ijnurstu.2011.02.005
Published
Issue
Section
License
Copyright (c) 2024 Vrusha Shah, Amar Desai, Shari Lipner
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
